Literature DB >> 8361790

Prenatal detection of neuroblastoma: a ten-year experience from the Dana-Farber Cancer Institute and Children's Hospital.

P T Ho1, J A Estroff, H Kozakewich, R C Shamberger, C W Lillehei, H E Grier, L Diller.   

Abstract

OBJECTIVES: To assess the relative frequency of, the clinical and pathological correlates in, and the prognosis of the subset of infants with neuroblastoma who were identified initially by prenatal ultrasonography.
DESIGN: Retrospective review of all patients with neuroblastoma evaluated between 1982 and 1992.
SETTING: Large, urban, tertiary care children's hospital in Boston, Massachusetts. PATIENTS: Eleven infants with neuroblastoma initially detected with prenatal sonograms were identified.
RESULTS: Nine patients had adrenal tumors; two had thoracic paraspinal tumors. Typical diagnostic evidence for neuroblastoma including a palpable abdominal mass and elevations in urinary catecholamines were not commonly seen postnatally. These patients had multiple favorable prognostic indicators including low stage of disease (10/11), favorable biological markers including cellular DNA content (5/5) and N-myc oncogene copy number (5/5), and histopathology suggestive for neuroblastoma in situ (7/11). All patients were treated by surgical resection. One patient exhibited progression of disease postoperatively, but demonstrated a complete clinical response to multiagent chemotherapy. Overall survival in our population was excellent with no deaths seen at a mean follow-up of 37 months (range 3 to 120 months).
CONCLUSIONS: Patients with neuroblastoma identified by prenatal ultrasonography generally, although not exclusively, follow a clinically favorable course in which surgical resection is curative. Chemotherapy is not indicated unless substantial progression of disease occurs.

Entities:  

Mesh:

Year:  1993        PMID: 8361790

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  14 in total

1.  Atrophic upper pole of a duplex collecting system masquerading as suprarenal mass: a case study and literature review.

Authors:  Alex Kavanagh; Iain McAuley; Michelle Longpre; Andrew E Macneily
Journal:  Can Urol Assoc J       Date:  2010-08       Impact factor: 1.862

2.  Stridor in a newborn.

Authors:  Reuben Antony; Abdulhakim Al-Rawas; Meredith Irwin
Journal:  CMAJ       Date:  2005-09-13       Impact factor: 8.262

Review 3.  Spontaneous regression of neuroblastoma.

Authors:  Garrett M Brodeur
Journal:  Cell Tissue Res       Date:  2018-01-05       Impact factor: 5.249

Review 4.  Mechanisms of neuroblastoma regression.

Authors:  Garrett M Brodeur; Rochelle Bagatell
Journal:  Nat Rev Clin Oncol       Date:  2014-10-21       Impact factor: 66.675

5.  Neonatal neuroblastoma.

Authors:  J Moppett; I Haddadin; A B Foot
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1999-09       Impact factor: 5.747

6.  Features and outcomes of neonatal neuroblastoma.

Authors:  B Kostyrka; J Li; S V Soundappan; J Cassey; F Alvaro; L Dalla Pozza; Rajendra Kumar
Journal:  Pediatr Surg Int       Date:  2011-06-28       Impact factor: 1.827

7.  HDAC6 deacetylates Ku70 and regulates Ku70-Bax binding in neuroblastoma.

Authors:  Chitra Subramanian; Jason A Jarzembowski; Anthony W Opipari; Valerie P Castle; Roland P S Kwok
Journal:  Neoplasia       Date:  2011-08       Impact factor: 5.715

8.  Neonatal neuroblastoma needs the aggressive treatment?

Authors:  So-Hyun Nam; Dae Yeon Kim; Seong Chul Kim; Jong-Jin Seo
Journal:  World J Surg       Date:  2012-09       Impact factor: 3.352

Review 9.  Neuroblastoma: a review of management and outcome.

Authors:  Sushmita Nitin Bhatnagar; Yogesh Kumar Sarin
Journal:  Indian J Pediatr       Date:  2012-04-18       Impact factor: 1.967

10.  A prospective study of expectant observation as primary therapy for neuroblastoma in young infants: a Children's Oncology Group study.

Authors:  Jed G Nuchtern; Wendy B London; Carol E Barnewolt; Arlene Naranjo; Patrick W McGrady; James D Geiger; Lisa Diller; Mary Lou Schmidt; John M Maris; Susan L Cohn; Robert C Shamberger
Journal:  Ann Surg       Date:  2012-10       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.